Vetoquinol corporate brochure 2017

tively fight against acute respiratory pathologies in cattle while minimising the risk of the development of bacteri- al resistance to antibiotics. > Pain and inflammation Vetoquinol proposes a comprehen- sive range of products to prevent and relieve pain. By contributing to animal well-being, the Group fulfils an ethical and therapeutic objective, as pain is known to have a damaging effect on health. > Cardio-nephrology Heart and kidney failure are respective- ly the most frequent chronic illnesses in elderly dogs and cats. In 2015, Vetoquinol launched Upcard ® , a genuinely innovative medecine which changes how veterinarians treat congestive heart failure. > Behaviour In parallel, Vetoquinol has moved into pet stress management, a market having grown considerably in the last five years. An innovative, patented product, Zylkène ® helps dogs and cats to cope with unusual and potentially disturbing situations. > Reproduction With the acquisition in 2014 of Bioniche Animal Health, a major player in reproduction, particu- larly in North America, Vetoquinol offers a complete range of products to support its customers from concep- tion through to birth. The Group is now one of the world leaders in this field, and this is primarily due to Folltropin ® . ENGAGED BY OUR PRODUCT STRATEGY 9 SOME OF OUR LEADING PRODUCTS Tolfédine ® CS Cefaseptin ® Clavaseptin ®